Bladder Bank (a Prospective Banking Study)
ConditionBladder Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This study collects blood and urine samples from patients with bladder cancer to support the development of tests for early detection of bladder cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age > 18 years
Patient has undergone office-based evaluation for hematuria [computed tomography (CT), ultrasound, cystoscopy]
Disqualifiers
Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible)
Patient has recurrent muscle invasive bladder cancer
Patient has ever been previously diagnosed with UTUC (upper tract urothelial carcinoma) prior to bladder resection
Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection
Trial population
Patient has undergone office-based evaluation for hematuria
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Non-Interventional Study
Other interventionNon-interventional study
Treatment groups
1,500 Participants
are divided into 1 treatment groupGroup A: Observational1 intervention
Trial outcomes
Primary outcomes
1
Blood sample to support the development of non-invasive tests for early detection of bladder cancer
At study enrollment for subjects, 60 ml (4 tablespoons) of blood will be drawn from all participants and processed according to standardized study biospecimen protocol. All samples will be stored for future analysis in Molecular Cancer Diagnostic Laboratory at Mayo Clinic.
Time frame
Baseline (at enrollment)2
Urine sample to support the development of non-invasive tests for early detection of bladder cancer
At study enrollment for subjects, up to 20mL of urine will be collected from the same or unique case patients identified for blood collection. All samples will be stored for future analysis in Molecular Cancer Diagnostic Laboratory at Mayo Clinic.
Time frame
Baseline (at enrollment)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov